The Parliamentary Secretary for Industry and Innovation, Mark Dreyfus, has appointed a panel to review the patenting of pharmaceuticals in Australia. According to the Terms of Reference, the review: will evaluate whether the system for pharmaceutical patents is effectively balancing the objectives of securing timely access to competitively priced pharmaceuticals, fostering innovation and supporting employment in research and industry. Central to this will be an analysis of the pharmaceutical extension of term provisions of.. Read More
The videocast of the 3rd Annual Francis Gurry Lecture is now available: De-linking intellectual property from exclusive rights by James Love, Director, Knowledge Ecology Limited. The blurb says: The traditional justification for IP rights-atemporary monopoly to stimulate innovation and inverstment-is increasingly being questioned. If knowledge is more valuable when widely shared, and if freedom to use knowledge is socially and economically important, we need to de-link intellectual property protection from exclusive rights. But.. Read More
IP Australia has issued a consultation paper on implementing the TRIPS protocol. The TRIPS protocol is the modification (or is that clarification?) of TRIPS obligations to improve the availability of “crisis” pharmaceuticals in least developed and developing countries. From the discussion paper: The TRIPS Protocol seeks to address this problem by amending the TRIPS Agreement to permit WTO members to issue compulsory licences to produce patented pharmaceutical products for export to least-developed and.. Read More
I’m not quite sure why, but the blogosphere is increasingly chattering again about relaxing the rules against infringing a patent by making the protected product (esp. a pharmaceutical) for export: Duncan Bucknell LawFont IP’s What’s Up reviews the TRIPS status including the DOHA declaration and its rather tentative take up.